Eisai Co Ltd
TSE:4523

Watchlist Manager
Eisai Co Ltd Logo
Eisai Co Ltd
TSE:4523
Watchlist
Price: 4 277 JPY 0.45% Market Closed
Market Cap: 1.2T JPY
Have any thoughts about
Eisai Co Ltd?
Write Note
Eisai Co Ltd
/
Cash Flow Statement
/
Capital Expenditures

Eisai Co Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eisai Co Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Eisai Co Ltd
TSE:4523
Capital Expenditures
-¥20.4B
CAGR 3-Years
21%
CAGR 5-Years
16%
CAGR 10-Years
1%
Takeda Pharmaceutical Co Ltd
TSE:4502
Capital Expenditures
-¥339.9B
CAGR 3-Years
-12%
CAGR 5-Years
-17%
CAGR 10-Years
-13%
Daiichi Sankyo Co Ltd
TSE:4568
Capital Expenditures
-¥169.7B
CAGR 3-Years
-42%
CAGR 5-Years
-20%
CAGR 10-Years
-12%
Otsuka Holdings Co Ltd
TSE:4578
Capital Expenditures
-¥141.7B
CAGR 3-Years
-26%
CAGR 5-Years
-14%
CAGR 10-Years
-7%
Chugai Pharmaceutical Co Ltd
TSE:4519
Capital Expenditures
-¥74.3B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
-15%
Astellas Pharma Inc
TSE:4503
Capital Expenditures
-¥76.4B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
-4%
No Stocks Found

Eisai Co Ltd
Glance View

Market Cap
1.2T JPY
Industry
Pharmaceuticals

Eisai Co., Ltd., established in 1941, has emerged as a formidable player in the global pharmaceutical landscape, forging its reputation through a steadfast commitment to "human health care" (hhc). Rooted in Tokyo, the company orbits around the development of innovative treatments targeting neurology and oncology, positioning itself as a beacon of hope for patients worldwide. Eisai's journey is characterized by a persistent focus on medicinal breakthroughs in areas such as Alzheimer’s disease, liver cancer, and epilepsy—disease states that critically affect the quality of life but often have limited treatment options. Through its rigorous research and development efforts, the company crafts both small molecule drugs and biologics, distinguishing itself with flagship products like Aricept for Alzheimer's and Lenvima for cancer, both of which have cemented its reputation in the medical community and are vital streams of revenue. Eisai's business framework is intricately woven into a global tapestry of partnerships and collaborations, which amplifies its market reach and bolsters its financial performance. By strategically aligning with global pharmaceutical giants and leveraging robust patent portfolios, Eisai extends its innovative therapies to numerous markets. This strategic network allows it to not only enhance drug distribution and sales but also to engage in co-development, introducing shared stewardship in groundbreaking research. The company's financial structure is further reinforced through a diversified portfolio, inclusive of both branded prescription drugs and over-the-counter products, thus facilitating consistent cash flow and enabling ongoing investments in research. These deliberate steps underscore Eisai's pursuit of longevity in a fiercely competitive industry, ensuring it remains well-poised to continually adapt and thrive amidst evolving healthcare challenges.

Intrinsic Value
7 097.77 JPY
Undervaluation 40%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Eisai Co Ltd's Capital Expenditures?
Capital Expenditures
-20.4B JPY

Based on the financial report for Sep 30, 2024, Eisai Co Ltd's Capital Expenditures amounts to -20.4B JPY.

What is Eisai Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
1%

Over the last year, the Capital Expenditures growth was 21%. The average annual Capital Expenditures growth rates for Eisai Co Ltd have been 21% over the past three years , 16% over the past five years , and 1% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.